EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy

Marianna Ciwun, Anna Tankiewicz-Kwedlo iD, Dariusz Pawlak iD

Cancers · 21.03.2024 · 16 (6) · 1240

DOI: 10.3390/cancers16061240 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.03.2024. Verfasst von Marianna Ciwun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok, Medical University of Bialystok.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Naltrexone (NTX) is a non-selective antagonist of opioid receptors, primarily used in the therapy of opioid and alcohol dependence. Low-dose naltrexone (LDN) exhibits antagonistic action against the opioid growth factor receptor (OGFr), whose signaling is associated with the survival, proliferation, and invasion of cancer cells. The mechanism of action of LDN depends on the dose and duration of the OGFr blockade, leading to a compensatory increase in the synthesis of the opioid growth factor (OGF), which has an inhibitory effect on carcinogenesis. Numerous studies on in vitro and in vivo models provide evidence of LDN’s positive impact on inhibiting the OGF–OGFr axis in cancers. LDN’s unique mechanism of action on cancer cells, lack of direct cytotoxic effect, and immunomodulating action form the basis for its use as an adjuvant in chemotherapy and immunotherapy of cancerous lesions.

Schlagwörter

Stichwörter der Autor:innen

adjuvantcancerlow-dose naltrexonenaltrexonesynergistic therapy

Autor:innen und Institutionen

  • Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.

ORCID-Profile: Anna Tankiewicz-Kwedlo, Dariusz Pawlak

Förderung

  • Medical University of Białystok
  • Medical University of Bialystok

Zitieren

APA

Ciwun, M., Tankiewicz-Kwedlo, A., & Pawlak, D. (2024). Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy. Cancers, 16(6), 1240. https://doi.org/10.3390/cancers16061240

Vancouver

Ciwun M, Tankiewicz-Kwedlo A, Pawlak D. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy. Cancers. 2024;16(6):1240. doi:10.3390/cancers16061240

BibTeX
@article{Ciwun2024,
  author = {Ciwun, Marianna and Tankiewicz-Kwedlo, Anna and Pawlak, Dariusz},
  title = {Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {1240},
  doi = {10.3390/cancers16061240}
}
Kostenlos starten →